ScholarIQanswers from OpenAlex & ORCID
Jean‐Yves Douillard
ResearcherPublications, citations & collaboration network
Jean‐Yves Douillard is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jean‐Yves Douillard have?
ScholarIQindexed works
Jean‐Yves Douillard has 383 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jean‐Yves Douillard have?
ScholarIQcitation count
Jean‐Yves Douillard has 33,552 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jean‐Yves Douillard?
ScholarIQh-index
Jean‐Yves Douillard has an h-index of 69 in OpenAlex.
What is the i10-index of Jean‐Yves Douillard?
ScholarIQi10-index
Jean‐Yves Douillard has an i10-index of 173 in OpenAlex.
What is the ORCID of Jean‐Yves Douillard?
ScholarIQorcid
The ORCID for Jean‐Yves Douillard is on the source record.
What is the OpenAlex record for Jean‐Yves Douillard?
ScholarIQopenalex
The OpenAlex for Jean‐Yves Douillard is on the source record.
What are the most-cited papers on Jean‐Yves Douillard?
ScholarIQmost cited works
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck, R. Kaiser, Anders Mellemgaard, Jean‐Yves Douillard, С. В. Орлов, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, Claudia-Nanette Gann, José Barrueco, Birgit Gaschler‐Markefski, Silvia Novello
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Takayuki Yoshino, Dirk Arnold, Hiroya Taniguchi, George Pentheroudakis, Kentaro Yamazaki, Rui‐Hua Xu, Tae‐Woo Kim, Muhammad Ismail, Iain Tan, Kun‐Huei Yeh, Axel Grothey, S. Zhang, Joong Bae Ahn, M.Y. Mastura, Dawn Q. Chong, Liqun Chen, Scott Kopetz, Takako Eguchi-Nakajima, Hiromichi Ebi, Atsushi Ohtsu, Andrés Cervantes, Kei Muro, Josep Tabernero, Hironobu Minami, Fortunato Ciardiello, Jean‐Yves Douillard
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
Primo N. Lara, Jean‐Yves Douillard, Kazuhiko Nakagawa, Joachim von Pawel, Mark J. McKeage, István Albert, György Losonczy, Martin Reck, Dae Seog Heo, Xiaolin Fan, Abderrahim Fandi, Giorgio V. Scagliotti